PDS Biotechnology Story

<div class='circular--portrait' style='background:#FF01C9;color: #FFF8DC;font-size:4em;'>PB</div>
PDSB -- USA Stock  

USD 2.73  0.26  8.70%

54% of stocks are less volatile than PDS Biotechnology, and 91% of all traded equity instruments are projected to make higher returns than the company over the 60 days investment horizon. As many conservative investors are still indifferent towards current market risk, it is prudent, from our point of view, to go over PDS Biotechnology's current volatility. We will analyze why some investors are closely monitoring PDS Biotechnology's volatility.
Published over a month ago
View all stories for PDS Biotechnology | View All Stories
Is PDS Biotechnology (NASDAQ:PDSB) rise trustworthy based on current volatility?
The company conducts business under Healthcare sector and is part of Biotechnology industry. On a scale of 0 to 100, PDS Biotechnology holds a performance score of 5. The company holds a Beta of -0.4937, which implies possible diversification benefits within a given portfolio. Let's try to break down what PDS Biotechnology's beta means in this case. As returns on the market increase, returns on owning PDS Biotechnology are expected to decrease at a much lower rate. During the bear market, PDS Biotechnology is likely to outperform the market. Although it is vital to follow PDS Biotechnology current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing price patterns. The approach into forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-seven technical indicators for PDS Biotechnology, which you can use to evaluate the performance of the company. Please employ PDS Biotechnology expected short fall, and the relationship between the value at risk and daily balance of power to make a quick decision on whether PDS Biotechnology historical price patterns will revert.
Volatility is a rate at which the price of PDS Biotechnology or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of PDS Biotechnology may increase or decrease. In other words, similar to PDS Biotechnology's beta indicator, it measures the risk of PDS Biotechnology and helps estimate the fluctuations that may happen in a short period of time. So if prices of PDS Biotechnology fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.

How important is PDS Biotechnology's Liquidity

PDS Biotechnology financial leverage refers to using borrowed capital as a funding source to finance PDS Biotechnology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. PDS Biotechnology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between PDS Biotechnology's total debt and its cash.

How PDS Biotechnology utilizes its cash?

To perform a cash flow analysis of PDS Biotechnology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash PDS Biotechnology is receiving and how much cash it distributes out in a given period. The PDS Biotechnology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Van Voorhees Seth of 202800 shares of PDS Biotechnology subject to Rule 16b-3

Legal trades by PDS Biotechnology insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
PDS Biotechnology insider trading alert for grant of stock option (right to buy) by Van Voorhees Seth, Chief Financial Officer, on 6th of January 2021. This event was filed by Pds Biotechnology Corp with SEC on 2021-01-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down PDS Biotechnology Further

Net Loss for the year was (15 M).

Will PDS Biotechnology current rise continue?

Current Jensen Alpha is up to 0.05. Price may slip again. PDS Biotechnology exhibits very low volatility with skewness of 0.57 and kurtosis of 1.24. However, we advise investors to further study PDS Biotechnology technical indicators to make sure all market info is available and is reliable.

Our Final Perspective on PDS Biotechnology

Whereas other companies under the biotechnology industry are still a bit expensive, PDS Biotechnology may offer a potential longer-term growth to investors. To conclude, as of the 5th of December 2020, we believe that at this point, PDS Biotechnology is very risky with very low probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. However, our concluding 30 days buy vs. sell advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of PDS Biotechnology. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com